This is the authors' abstract. We don't add key points for this paper.
The growing therapeutic use of cannabinoid-based formulations and the expanding heterogeneity of available cannabis products have created a pressing need for analytical methods capable of simultaneously monitoring a wide spectrum of pharmacologically relevant cannabinoids in blood. Currently, no fully validated HPLC–MS/MS method is available for the comprehensive analysis of a multi-cannabinoid panel in whole blood collected via volumetric dried microsampling. To address this gap, we report the development, optimisation and full validation of an HPLC–MS/MS method for the simultaneous quantification of nine cannabinoids, namely cannabidiol (CBD), 7-hydroxy-CBD (7-OH-CBD), 7-carboxy-CBD (7-COOH-CBD), 6α-hydroxy-CBD (6α-OH-CBD), cannabinol (CBN), cannabigerol (CBG), Δ9-tetrahydrocannabinol (Δ9-THC), 11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-THC (THC-COOH), in whole blood collected as advanced volumetric dried blood microsamples using the hemaPEN® device. Chromatographic separation was achieved on a C8 column with electrospray ionisation in polarity switching. A dual-protocol extraction strategy was introduced to address the wide dynamic range of cannabinoid concentrations in blood: analytes with high expected concentrations (THC-COOH, CBD, 7-OH-CBD and 7-COOH-CBD) were quantified from a single hemaPEN disc (2.74 µL; LLOQs 2.0–5.0 ng/mL), while Δ9-THC, 11-OH-THC, 6α-OH-CBD, CBN and CBG, requiring enhanced sensitivity, were extracted from all four pooled discs (10.96 µL; LLOQ 0.5 ng/mL for Δ9-THC, 11-OH-THC, 6α-OH-CBD, CBN and CBG). This strategy uniquely exploits the four-replicate architecture of the technology, which generates four volumetrically identical dried blood spots by capillary action from a single fingerstick. The method was validated for selectivity, linearity, precision, accuracy, extraction yield, matrix effect, hematocrit independence and stability. Extraction yield ranged from 67.8% to 81.7%; IS-normalised matrix effect ranged from 89.6% to 98.6% across six donor matrices. Room-temperature stability was confirmed for at least 90 days for the complete analyte panel. The method was applied to authentic blood specimens, demonstrating successful quantification across the full nine-cannabinoid panel. The present method provides a validated, logistically practical tool for forensic and toxicological cannabinoid monitoring, therapeutic drug monitoring (TDM) in patients receiving cannabinoid-based treatments, and pharmacokinetic characterisation in clinical and preclinical research.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Noreen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: